These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 36113782)

  • 41. Atypical 15q11.2-q13 Deletions and the Prader-Willi Phenotype.
    Grootjen LN; Juriaans AF; Kerkhof GF; Hokken-Koelega ACS
    J Clin Med; 2022 Aug; 11(15):. PubMed ID: 35956251
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alteration of serum leptin and LEP/LEPR promoter methylation in Prader-Willi syndrome.
    Wieting J; Jahn K; Buchholz V; Lichtinghagen R; Deest-Gaubatz S; Bleich S; Eberlein CK; Deest M; Frieling H
    Psychoneuroendocrinology; 2022 Sep; 143():105857. PubMed ID: 35803048
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SNORD116 and growth hormone therapy impact IGFBP7 in Prader-Willi syndrome.
    Eddiry S; Diene G; Molinas C; Salles J; Auriol FC; Gennero I; Bieth E; Skryabin BV; Rozhdestvensky TS; Burnett LC; Leibel RL; Tauber M; Salles JP
    Genet Med; 2021 Sep; 23(9):1664-1672. PubMed ID: 34040195
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oxytocin receptors in the Magel2 mouse model of autism: Specific region, age, sex and oxytocin treatment effects.
    Gigliucci V; Busnelli M; Santini F; Paolini C; Bertoni A; Schaller F; Muscatelli F; Chini B
    Front Neurosci; 2023; 17():1026939. PubMed ID: 36998737
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Paternally inherited microdeletion at 15q11.2 confirms a significant role for the SNORD116 C/D box snoRNA cluster in Prader-Willi syndrome.
    Duker AL; Ballif BC; Bawle EV; Person RE; Mahadevan S; Alliman S; Thompson R; Traylor R; Bejjani BA; Shaffer LG; Rosenfeld JA; Lamb AN; Sahoo T
    Eur J Hum Genet; 2010 Nov; 18(11):1196-201. PubMed ID: 20588305
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment.
    Höybye C
    Growth Horm IGF Res; 2004 Feb; 14(1):1-15. PubMed ID: 14700552
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Peptides associated with hyperphagia in adults with Prader-Willi syndrome before and during GH treatment.
    Höybye C; Barkeling B; Espelund U; Petersson M; Thorén M
    Growth Horm IGF Res; 2003 Dec; 13(6):322-7. PubMed ID: 14624765
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial.
    Roof E; Deal CL; McCandless SE; Cowan RL; Miller JL; Hamilton JK; Roeder ER; McCormack SE; Roshan Lal TR; Abdul-Latif HD; Haqq AM; Obrynba KS; Torchen LC; Vidmar AP; Viskochil DH; Chanoine JP; Lam CKL; Pierce MJ; Williams LL; Bird LM; Butler MG; Jensen DE; Myers SE; Oatman OJ; Baskaran C; Chalmers LJ; Fu C; Alos N; McLean SD; Shah A; Whitman BY; Blumenstein BA; Leonard SF; Ernest JP; Cormier JW; Cotter SP; Ryman DC
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1696-1708. PubMed ID: 36633570
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hypomethylation of the dopamine transporter (DAT) gene promoter is associated with hyperphagia-related behavior in Prader-Willi syndrome: A case-control study.
    Wieting J; Jahn K; Eberlein CK; Bleich S; Frieling H; Deest M
    Behav Brain Res; 2023 Jul; 450():114494. PubMed ID: 37182741
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome: A narrative review.
    Tan Q; Orsso CE; Deehan EC; Triador L; Field CJ; Tun HM; Han JC; Müller TD; Haqq AM
    Obes Rev; 2020 May; 21(5):e12992. PubMed ID: 31889409
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biomarker discovery for disease status and symptom severity in children with autism.
    Oztan O; Jackson LP; Libove RA; Sumiyoshi RD; Phillips JM; Garner JP; Hardan AY; Parker KJ
    Psychoneuroendocrinology; 2018 Mar; 89():39-45. PubMed ID: 29309996
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Malignancies in Prader-Willi Syndrome: Results From a Large International Cohort and Literature Review.
    Pellikaan K; Nguyen NQC; Rosenberg AGW; Coupaye M; Goldstone AP; Høybye C; Markovic T; Grugni G; Crinò A; Caixàs A; Poitou C; Corripio R; Nieuwenhuize RM; van der Lely AJ; de Graaff LCG
    J Clin Endocrinol Metab; 2023 Nov; 108(12):e1720-e1730. PubMed ID: 37267430
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prader-Willi Syndrome and Chromosome 15q11.2 BP1-BP2 Region: A Review.
    Butler MG
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901699
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction.
    Tauber M; Hoybye C
    Lancet Diabetes Endocrinol; 2021 Apr; 9(4):235-246. PubMed ID: 33647242
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential DNA methylation in iPSC-derived dopaminergic neurons: a step forward on the role of SNORD116 microdeletion in the pathophysiology of addictive behavior in Prader-Willi syndrome.
    Salles J; Eddiry S; Amri S; Galindo M; Lacassagne E; George S; Mialhe X; Lhuillier É; Franchitto N; Jeanneteau F; Gennero I; Salles JP; Tauber M
    Mol Psychiatry; 2024 Sep; 29(9):2742-2752. PubMed ID: 38561465
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oxytocin treatment in children with Prader-Willi syndrome: A double-blind, placebo-controlled, crossover study.
    Miller JL; Tamura R; Butler MG; Kimonis V; Sulsona C; Gold JA; Driscoll DJ
    Am J Med Genet A; 2017 May; 173(5):1243-1250. PubMed ID: 28371242
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome.
    Einfeld SL; Smith E; McGregor IS; Steinbeck K; Taffe J; Rice LJ; Horstead SK; Rogers N; Hodge MA; Guastella AJ
    Am J Med Genet A; 2014 Sep; 164A(9):2232-9. PubMed ID: 24980612
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expressive and receptive language in Prader-Willi syndrome: report on genetic subtype differences.
    Dimitropoulos A; Ferranti A; Lemler M
    J Commun Disord; 2013; 46(2):193-201. PubMed ID: 23295077
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prader-Willi Syndrome: Clinical Genetics and Diagnostic Aspects with Treatment Approaches.
    Butler MG; Manzardo AM; Forster JL
    Curr Pediatr Rev; 2016; 12(2):136-66. PubMed ID: 26592417
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Central vasopressin and oxytocin release: regulation of complex social behaviours.
    Veenema AH; Neumann ID
    Prog Brain Res; 2008; 170():261-76. PubMed ID: 18655888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.